MedTrace Logo

Impact of Amantadine on Traumatic Brain Injury

NCT04527289 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-04-07

No results posted yet for this study

Summary

The aim of this study is to evaluate whether the addition of amantadine to the management regimen of traumatic brain injury patients would have a favorable effect on recovery and neurological complications in association with prognosis biomarkers Interleukin-18 (IL-18), Neuron-specific enolase (NSE) and (Neurotensin).

Conditions

  • Trauma, Brain

Interventions

DRUG

Amantadine (100mg) as add on therapy.

Amantadine (100mg) as add on therapy to the management regimen of traumatic brain injury - 100mg twice daily Oral or feeding tube

DRUG

Placebo

patients will be managed with placebo as add on to the standard regimen.

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Rehab H Werida, Lecturer · Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-10-01
Completion
2021-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04527289 on ClinicalTrials.gov